Evidence map›Paper›PMID 39673290›Full record

ArticleJournal of the American Heart Association2024

Increased Plasma

Ya Su, Qiong Wang, Feng Gao, Jiajie Xu, Jiayu Fu, Yunqing Ying, Yiwei Xia, Xiaoxiao Wang, Qiang Dong, Yong Shen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ya SuDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Center for Aging and Medicine Huashan Hospital, Fudan University Shanghai China.ORCID 0000-0002-2689-3148
Qiong WangNeurodegenerative Disorder Research Center, Division of Life Sciences and Medicine University of Science and Technology of China Hefei China.
Feng GaoNeurodegenerative Disorder Research Center, Division of Life Sciences and Medicine University of Science and Technology of China Hefei China.ORCID 0000-0002-7539-6455
Jiajie XuDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Center for Aging and Medicine Huashan Hospital, Fudan University Shanghai China.
Jiayu FuDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Center for Aging and Medicine Huashan Hospital, Fudan University Shanghai China.
Yunqing YingDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Center for Aging and Medicine Huashan Hospital, Fudan University Shanghai China.ORCID 0000-0001-9421-5683
Yiwei XiaDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Center for Aging and Medicine Huashan Hospital, Fudan University Shanghai China.ORCID 0000-0002-8184-1228
Xiaoxiao WangHefei National Lab for Physical Sciences at the Microscale and the Centers for Biomedical Engineering University of Science and Technology of China Hefei China.ORCID 0000-0002-8498-7388
Qiang DongDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Center for Aging and Medicine Huashan Hospital, Fudan University Shanghai China.
Yong ShenNeurodegenerative Disorder Research Center, Division of Life Sciences and Medicine University of Science and Technology of China Hefei China.ORCID 0000-0002-5048-8134
Xin ChengDepartment of Neurology, National Center for Neurological Disorders, National Clinical Research Center for Aging and Medicine Huashan Hospital, Fudan University Shanghai China.ORCID 0000-0001-7816-0547

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMETHODS AND

resultsWe enrolled 163 participants with CSVD (114 cerebral amyloid angiopathy and 49 hypertensive hemorrhage), and 96 cognitively unimpaired elders and 40 participants with Alzheimer's disease as controls. We measured BACE1 activity using a synthetic fluorescence substrate enzyme-linked immunosorbent assay. We used regression models to investigate associations between BACE1 and imaging and blood markers as well as clinical outcomes in CSVD. Plasma BACE1 activity was significantly higher in CSVD (median 862.0 relative fluorescence units [RFU], interquartile range 700.6-1032.9) compared with elder controls (522.5 RFU, 438.3-662.1,

conclusionsPlasma BACE1 activity is moderately increased and associated with neurodegeneration and cognitive impairment risk in CSVD. It indicates that BACE1 is a promising biomarker especially for CSVD-related neurodegeneration.

Indexed as

Amyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBiomarkersCerebral Small Vessel DiseasesAgedAged, 80 and overAlzheimer DiseaseCase-Control StudiesCerebral Amyloid AngiopathyEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedUp-RegulationAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBACE1 protein, humanBiomarkerscerebral amyloid angiopathycerebral small vessel diseasehypertensive arteriopathyneurodegenerationβ‐secretase 1

Identifiers

PMID39673290
PMCPMC11935555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.